Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The effect of carboxylesterase 1 (CES1) polymorphisms on the pharmacokinetics of oseltamivir in humans.

European journal of clinical pharmacology - 1 Jan 2013

Suzaki Yuki, Uemura Naoto, Takada Makoto, Ohyama Tetsuji, Itohda Akiko, Morimoto Takuya, Imai Hiromitsu, Hamasaki Hajime, Inano Akihiro, Hosokawa Masakiyo, Tateishi Masato, Ohashi Kyoichi

Abstract excerpt

PURPOSE: The aim of this study was to examine whether carboxylesterase 1 (CES1A) genetic polymorphisms affect the pharmacokinetics of oseltamivir. METHODS: Thirty healthy Japanese male and female subjects ranging in age from 20 to 36 years voluntarily participated in this study. These subjects were administered a single 75-mg dose of oseltamivir (Tamiflu®), and blood samples were collected predose and up to 24 h...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Asian People

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carboxylic Ester Hydrolases

Share to Cholinesterase and Neurodegenerative Diseases

Share to Genotype

Share to Oseltamivir

Share to Polymorphism, Genetic

Share to Young Adult

Source

Identifiers

PMID: 22673926
DOI: 10.1007/s00228-012-1315-5

Genes

CES1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The effect of carboxylesterase 1 (CES1) polymorphisms on the pharmacokinetics of oseltamivir in humans.PMID 22673926Read ↗

The novel carboxylesterase 1 variant c.662A>G may decrease the bioactivation of oseltamivir in humans.Semantic proximity Read ↗

Carboxylesterase 1 polymorphism impairs oseltamivir bioactivation in humans.Semantic proximity Read ↗

Association of Oseltamivir Activation with Gender and Carboxylesterase 1 Genetic Polymorphisms.Semantic proximity Read ↗

The pharmacogenetics of carboxylesterases: CES1 and CES2 genetic variants and their clinical effect.Semantic proximity Read ↗

Physiologically Based Pharmacokinetic Modeling of Impaired Carboxylesterase-1 Activity: Effects on Oseltamivir DispositionSemantic proximity Read ↗

Role of the ABCB1 Drug Transporter Polymorphisms in the Pharmacokinetics of Oseltamivir in Humans: a Preliminary Report.Semantic proximity Read ↗

Activation of the antiviral prodrug oseltamivir is impaired by two newly identified carboxylesterase 1 variants.Semantic proximity Read ↗

A simple allele-specific polymerase chain reaction method to detect the Gly143Glu polymorphism in the human carboxylesterase 1 gene: importance of genotyping for pharmacogenetic treatment.Semantic proximity Read ↗

Association of carboxylesterase 1A genotypes with irinotecan pharmacokinetics in Japanese cancer patients.Semantic proximity Read ↗

The Impact of Carboxylesterases in Drug Metabolism and PharmacokineticsSemantic proximity Read ↗

Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis.Semantic proximity Read ↗

Carboxylesterase 1 and Precision Pharmacotherapy: Pharmacogenetics and Nongenetic Regulators.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.